{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:24:06Z","timestamp":1783347846497,"version":"3.54.6"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01809-z","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:27:52Z","timestamp":1783344472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-Generation Checkpoint Combinations: Optimizing PD-(L)1\u2013Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-4486","authenticated-orcid":false,"given":"Fausto","family":"Petrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Colombo Zefinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dottorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ghidini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"12","key":"1809_CR1","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma (KEYNOTE-426). N Engl J Med. 2019;380(12):1116\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1816714.","journal-title":"N Engl J Med"},{"issue":"7","key":"1809_CR2","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","volume":"23","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): final follow-up. Presented ASCO GU 2025; Lancet Oncol. 2022;23(7):888\u201398. https:\/\/doi.org\/10.1016\/S1470-2045(22)00290-X.","journal-title":"Presented ASCO GU 2025; Lancet Oncol"},{"key":"1809_CR3","doi-asserted-by":"publisher","unstructured":"Motzer R, Alekseev B, Rha SY et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma (CLEAR). N Engl J Med. 2021;384(14):1289\u20131300; final OS analysis J Clin Oncol. 2024;42(11):1222\u20131228. https:\/\/doi.org\/10.1056\/NEJMoa2035716","DOI":"10.1056\/NEJMoa2035716"},{"issue":"12","key":"1809_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma (JAVELIN Renal 101). N Engl J Med. 2019;380(12):1103\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1816047.","journal-title":"N Engl J Med"},{"issue":"8","key":"1809_CR5","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma (KEYNOTE-564). N Engl J Med. 2021;385(8):683\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2106391. 5-year follow-up presented ASCO 2025.","journal-title":"N Engl J Med"},{"issue":"10358","key":"1809_CR6","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","volume":"400","author":"SK Pal","year":"2022","unstructured":"Pal SK, Uzzo R, Karam JA, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010). Lancet. 2022;400(10358):1103\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(22)01658-0.","journal-title":"Lancet"},{"issue":"10379","key":"1809_CR7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","volume":"401","author":"RJ Motzer","year":"2023","unstructured":"Motzer RJ, Russo P, Gr\u00fcnwald V, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914). Lancet. 2023;401(10379):821\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(22)02574-0.","journal-title":"Lancet"},{"issue":"11","key":"1809_CR8","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.annonc.2024.07.723","volume":"35","author":"ME Allaf","year":"2024","unstructured":"Allaf ME, Kim SE, Harshman LC, et al. Perioperative nivolumab versus observation in patients with renal cell carcinoma (PROSPER ECOG-ACRIN EA8143). Ann Oncol. 2024;35(11):1038\u201346. https:\/\/doi.org\/10.1016\/j.annonc.2024.07.723.","journal-title":"Ann Oncol"},{"key":"1809_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313906","author":"L Albiges","year":"2024","unstructured":"Albiges L, Rini BI, Peltola K, et al. Belzutifan versus everolimus in participants with previously treated advanced clear cell renal cell carcinoma (LITESPARK-005). N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2313906.","journal-title":"N Engl J Med"},{"issue":"5","key":"1809_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S1470-2045(23)00097-9","volume":"24","author":"TK Choueiri","year":"2023","unstructured":"Choueiri TK, McDermott DF, Merchan J, et al. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma (LITESPARK-003): a phase 2 study. Lancet Oncol. 2023;24(5):553\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(23)00097-9.","journal-title":"Lancet Oncol"},{"issue":"16suppl","key":"1809_CR11","doi-asserted-by":"publisher","first-page":"TPS4602","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4602","volume":"40","author":"TK Choueiri","year":"2022","unstructured":"Choueiri TK, Bedke J, Karam JA, et al. LITESPARK-022: A phase 3 study of pembrolizumab plus belzutifan as adjuvant treatment of clear cell renal cell carcinoma. J Clin Oncol. 2022;40(16suppl):TPS4602. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS4602.","journal-title":"J Clin Oncol"},{"key":"1809_CR12","doi-asserted-by":"publisher","unstructured":"Powles T, Valderrama BP, Gupta S et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer (EV-302\/KEYNOTE-A39). N Engl J Med. 2024;390(10):875\u2013888; 2.5-year update Ann Oncol. 2025;36(10):1212\u20131219. https:\/\/doi.org\/10.1056\/NEJMoa2312117","DOI":"10.1056\/NEJMoa2312117"},{"issue":"19","key":"1809_CR13","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD, et al. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer (NIAGARA). N Engl J Med. 2024;391(19):1773\u201386. https:\/\/doi.org\/10.1056\/NEJMoa2408154.","journal-title":"N Engl J Med"},{"issue":"22","key":"1809_CR14","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma (CheckMate 274). N Engl J Med. 2021;384(22):2102\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2034442.","journal-title":"N Engl J Med"},{"issue":"1","key":"1809_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo AB, Ballman KV, Sonpavde GP, et al. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR, Alliance A031501). N Engl J Med. 2025;392(1):45\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2401726.","journal-title":"N Engl J Med"},{"issue":"6suppl","key":"1809_CR16","doi-asserted-by":"publisher","first-page":"TPS585","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS585","volume":"41","author":"MD Galsky","year":"2023","unstructured":"Galsky MD, Necchi A, Shore ND, et al. Perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer (KEYNOTE-905\/EV-303 and KEYNOTE-B15\/EV-304): trial designs. J Clin Oncol. 2023;41(6suppl):TPS585. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.TPS585.","journal-title":"J Clin Oncol"},{"issue":"19","key":"1809_CR17","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive NSCLC (KEYNOTE-024). N Engl J Med. 2016;375(19):1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med"},{"issue":"22","key":"1809_CR18","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-189). N Engl J Med. 2018;378(22):2078\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1801005.","journal-title":"N Engl J Med"},{"issue":"21","key":"1809_CR19","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer (KEYNOTE-407). N Engl J Med. 2018;379(21):2040\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1810865.","journal-title":"N Engl J Med"},{"issue":"2","key":"1809_CR20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in NSCLC (CheckMate 9LA). Lancet Oncol. 2021;22(2):198\u2013211. https:\/\/doi.org\/10.1016\/S1470-2045(20)30641-0.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1809_CR21","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, Abreu DR, Hussein M, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE). Lancet Oncol. 2022;23(6):781\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(22)00226-1.","journal-title":"Lancet Oncol"},{"issue":"21","key":"1809_CR22","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer (CheckMate 816). N Engl J Med. 2022;386(21):1973\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2202170.","journal-title":"N Engl J Med"},{"key":"1809_CR23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502931","author":"PM Forde","year":"2025","unstructured":"Forde PM, Spicer JD, Provencio M, et al. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Resectable NSCLC (CheckMate 816 final analysis). N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2502931.","journal-title":"N Engl J Med"},{"issue":"10459","key":"1809_CR24","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","volume":"404","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Garassino MC, Wakelee H, et al. Overall survival with perioperative pembrolizumab in resectable non-small-cell lung cancer (KEYNOTE-671). Lancet. 2024;404(10459):1240\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(24)01756-2.","journal-title":"Lancet"},{"issue":"18","key":"1809_CR25","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer (AEGEAN). N Engl J Med. 2023;389(18):1672\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2304875.","journal-title":"N Engl J Med"},{"issue":"19","key":"1809_CR26","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone T, Awad MM, Spicer JD, et al. Perioperative Nivolumab in Resectable Lung Cancer (CheckMate 77T). N Engl J Med. 2024;390(19):1756\u201369. https:\/\/doi.org\/10.1056\/NEJMoa2311926.","journal-title":"N Engl J Med"},{"issue":"3","key":"1809_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","volume":"331","author":"S Lu","year":"2024","unstructured":"Lu S, Zhang W, Wu L, et al. Perioperative Toripalimab plus Chemotherapy for Resectable Non-Small Cell Lung Cancer (Neotorch). JAMA. 2024;331(3):201\u201311. https:\/\/doi.org\/10.1001\/jama.2023.24735.","journal-title":"JAMA"},{"issue":"10308","key":"1809_CR28","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010). Lancet. 2021;398(10308):1344\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(21)02098-5.","journal-title":"Lancet"},{"issue":"10","key":"1809_CR29","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","volume":"23","author":"M O\u2019Brien","year":"2022","unstructured":"O\u2019Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA NSCLC (PEARLS\/KEYNOTE-091). Lancet Oncol. 2022;23(10):1274\u201386. https:\/\/doi.org\/10.1016\/S1470-2045(22)00518-6.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1809_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","volume":"31","author":"GR Oxnard","year":"2020","unstructured":"Oxnard GR, Yang JC, Yu H, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020;31(4):507\u201316. https:\/\/doi.org\/10.1016\/j.annonc.2020.01.013.","journal-title":"Ann Oncol"},{"issue":"1","key":"1809_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma (RELATIVITY-047). N Engl J Med. 2022;386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970.","journal-title":"N Engl J Med"},{"issue":"6382","key":"1809_CR32","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135. https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Science"},{"issue":"2","key":"1809_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","volume":"20","author":"P Sharma","year":"2020","unstructured":"Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 2020;20(2):75\u20136. https:\/\/doi.org\/10.1038\/s41577-020-0275-8.","journal-title":"Nat Rev Immunol"},{"issue":"10240","key":"1809_CR34","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150). Lancet. 2020;395(10240):1835\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(20)30934-X.","journal-title":"Lancet"},{"issue":"13","key":"1809_CR35","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.21.01601","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer R, Long GV, Robert C, et al. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Melanoma (COMBI-i). J Clin Oncol. 2022;40(13):1428\u201338. https:\/\/doi.org\/10.1200\/JCO.21.01601.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1809_CR36","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","volume":"5","author":"S Vinayak","year":"2019","unstructured":"Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer (TOPACIO\/KEYNOTE-162). JAMA Oncol. 2019;5(8):1132\u201340. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1029.","journal-title":"JAMA Oncol"},{"issue":"9","key":"1809_CR37","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","volume":"21","author":"SM Domchek","year":"2020","unstructured":"Domchek SM, Postel-Vinay S, Im SA, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA). Lancet Oncol. 2020;21(9):1155\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(20)30324-7.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1809_CR38","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","volume":"5","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019;5(8):1141\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1048.","journal-title":"JAMA Oncol"},{"issue":"7","key":"1809_CR39","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","volume":"39","author":"L Pusztai","year":"2021","unstructured":"Pusztai L, Yau C, Wolf DM, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer (I-SPY2). Cancer Cell. 2021;39(7):989\u2013e9985. https:\/\/doi.org\/10.1016\/j.ccell.2021.05.009.","journal-title":"Cancer Cell"},{"issue":"10","key":"1809_CR40","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","volume":"21","author":"LA Emens","year":"2020","unstructured":"Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2). Lancet Oncol. 2020;21(10):1283\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(20)30465-4.","journal-title":"Lancet Oncol"},{"issue":"7890","key":"1809_CR41","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Ya\u00f1ez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727\u201330. https:\/\/doi.org\/10.1038\/s41586-021-04161-3.","journal-title":"Nature"},{"issue":"17","key":"1809_CR42","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"Chesney J, Puzanov I, Collichio F, et al. Randomized, Open-Label Phase II Study of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Advanced Melanoma. J Clin Oncol. 2018;36(17):1658\u201367. https:\/\/doi.org\/10.1200\/JCO.2017.73.7379.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1809_CR43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott PA, Hu-Lieskovan S, Chmielowski B, et al. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Advanced Melanoma, NSCLC, or Bladder Cancer. Cell. 2020;183(2):347\u2013e36224. https:\/\/doi.org\/10.1016\/j.cell.2020.08.053.","journal-title":"Cell"},{"issue":"7662","key":"1809_CR44","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222\u20136. https:\/\/doi.org\/10.1038\/nature23003.","journal-title":"Nature"},{"issue":"10","key":"1809_CR45","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.3390\/cancers15102858","volume":"15","author":"B Li","year":"2023","unstructured":"Li B, Jin J, Guo D, Tao Z, Hu X. Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials. Cancers (Basel). 2023;15(10):2858. https:\/\/doi.org\/10.3390\/cancers15102858.","journal-title":"Cancers (Basel)"},{"key":"1809_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1616872","volume":"16","author":"C Tong","year":"2025","unstructured":"Tong C, Wu Y, Wu R. New dimensions of PD-1\/PD-L1 inhibitor combination therapy in cancer treatment: current advances and future perspectives. Front Immunol. 2025;16:1616872. https:\/\/doi.org\/10.3389\/fimmu.2025.1616872.","journal-title":"Front Immunol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01809-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01809-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01809-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:27:53Z","timestamp":1783344473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01809-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1809"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01809-z","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}